Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
📊
AI Sentiment
Positive
6/10
- Home
- RCUS
as of 03-27-2026 3:58pm EST
$20.29
$0.93
-4.36%
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 2.8B | IPO Year: | 2018 |
| Target Price: | $29.20 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.29 | EPS Growth: | -4.78 |
| 52 Week Low/High: | $6.79 - $26.40 | Next Earning Date: | 05-05-2026 |
| Revenue: | $247,000,000 | Revenue Growth: | -4.26% |
| Revenue Growth (this year): | -60.92% | Revenue Growth (next year): | 70.88% |
| P/E Ratio: | -6.45 | Index: | N/A |
| Free Cash Flow: | -484000000.0 | FCF Growth: | N/A |
AI-Powered RCUS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 76.54%
76.54%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Arcus Biosciences Inc. (RCUS)
Jaen Juan C.
Sell
President
RCUS Jan 5, 2026
Avg Cost/Share
$22.29
Shares
31,823
Total Value
$681,341.82
Owned After
924,393
Goeltz II Robert C.
Sell
Chief Financial Officer
RCUS Dec 31, 2025
Avg Cost/Share
$23.38
Shares
6,552
Total Value
$153,185.76
Owned After
67,924
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Jaen Juan C. | RCUS | President | Jan 5, 2026 | Sell | $22.29 | 31,823 | $681,341.82 | 924,393 | |
| Goeltz II Robert C. | RCUS | Chief Financial Officer | Dec 31, 2025 | Sell | $23.38 | 6,552 | $153,185.76 | 67,924 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 25, 2026 · 97% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 25, 2026 · 97% conf.
AI Prediction BUY
1D
+4.25%
$21.13
Act: -3.60%
5D
+6.65%
$21.62
Act: +11.89%
20D
+12.42%
$22.79
Price: $20.27 Prob +5D: 98% AUC: 1.000
0001724521-26-000007
rcus-20260225false000172452100017245212026-02-252026-02-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026
Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-3841947-3898435 (State or Other Jurisdiction of Incorporation) (Commission File Number)(IRS Employer Identification No.)
3928 Point Eden Way Hayward, California 94545 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (510) 694-6200 (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per ShareRCUSThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On February 25, 2026, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months and full year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit No.Description 99.1Press release dated February 25, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ARCUS BIOSCIENCES, INC.
Date: February 25, 2026 By:/s/ Terry Rosen, Ph. D. Terry Rosen, Ph.D. Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 28, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 28, 2025
0001724521-25-000114
rcus-20251028false000172452100017245212025-10-282025-10-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025
Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-3841947-3898435 (State or Other Jurisdiction of Incorporation) (Commission File Number)(IRS Employer Identification No.)
3928 Point Eden Way Hayward, California 94545 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (510) 694-6200 (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per ShareRCUSThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On October 28, 2025, Arcus Biosciences, Inc. issued a press release announcing its financial results for the nine months ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit No.Description 99.1Press release dated October 28, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ARCUS BIOSCIENCES, INC.
Date: October 28, 2025 By:/s/ Terry Rosen, Ph. D. Terry Rosen, Ph.D. Chief Executive Officer (Principal Executive Officer)
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 6, 2025
0001724521-25-000099
rcus-20250806false000172452100017245212025-08-062025-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025
Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-3841947-3898435 (State or Other Jurisdiction of Incorporation) (Commission File Number)(IRS Employer Identification No.)
3928 Point Eden Way Hayward, California 94545 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (510) 694-6200 (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per ShareRCUSThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On August 6, 2025, Arcus Biosciences, Inc. issued a press release announcing its financial results for the six months ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit No.Description 99.1Press release dated August 6, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ARCUS BIOSCIENCES, INC.
Date: August 6, 2025 By:/s/ Terry Rosen, Ph. D. Terry Rosen, Ph.D. Chief Executive Officer (Principal Executive Officer)
Latest Arcus Biosciences Inc. News
RCUS Breaking Stock News: Dive into RCUS Ticker-Specific Updates for Smart Investing
MT Newswires
Damora Therapeutics Names Jennifer Jarrett as CEO, Peter Harwin as Chairman
➖
AI Sentiment
Neutral
5/10
Compare RCUS vs Leading Stocks
See how RCUS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RCUS Arcus Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.